Group 1 - The core viewpoint of the article highlights the recent IPO of Baize Medical (02609.HK), which saw its stock price surge over 42% on its first trading day, indicating strong market interest despite lower subscription rates compared to peers [1][3] - Baize Medical issued 133 million shares at a price of HKD 4.22 per share, raising a net total of HKD 468 million, with only 12.20% of shares allocated for public offering in Hong Kong [1][6] - The company operates eight hospitals across several provinces in China, focusing on providing comprehensive cancer care services, including screening, diagnosis, treatment, and rehabilitation [5][6] Group 2 - Despite the strong debut, there are concerns regarding the company's fundamentals, as it has reported significant losses in recent years, although adjusted profits are projected for 2024 [2][4][6] - The revenue growth from 2022 to 2024 shows a compound annual growth rate of approximately 21.7%, with total revenues increasing from RMB 803 million to RMB 1.189 billion [5][6] - The company has a high goodwill amounting to RMB 643 million, primarily from recent acquisitions, which poses a risk if any impairment occurs [6]